All News

For the first time, clinicians have solid evidence from a large, long-term study that kidney donors have survival rates similar to those of the general population, and that donors are at no higher risk for developing end-stage renal disease, hypertension, diabetes, and cancer than non-donors are.

In patients with bladder cancer, tumor characteristics at presentation are less favorable in women and African-Americans versus Caucasian men, according to a study by researchers at the University of Rochester, New York.

By losing just 8% of their total body weight, overweight and obese women can significantly reduce the frequency of urinary incontinence episodes, according to results of a multicenter trial.

Using a relatively novel approach to identify microalterations differentiating benign prostatic disease from clinically localized prostate cancer and its progression to metastatic disease, researchers at the University of Michigan have identified a series of metabolites that they believe hold promise for use as biomarkers of tumor aggressiveness and invasiveness.

Focal therapy for prostate cancer has been surrounded by controversy due to the multifocal nature of the disease. Emerging evidence for a biologically dominant or index tumor, however, has the potential to shift the paradigm to focal therapy in carefully selected patients, according to experts speaking at the Medical Innovation Summit at Cleveland Clinic.

A visit to this third-largest U.S. city puts you at the heart of a gastronomic paradise.

National Cancer Institute Specialized Program of Research Excellence (SPORE) in Prostate Cancer

Clinical Centers of Excellence - Prostate Cancer: Memorial Sloan-Kettering Cancer Center by the numbers

Clinical Centers of Excellence - Prostate Cancer: Mayo Clinic by the numbers

Johns Hopkins' James Buchanan Brady Urological Institute in fiscal 2008 received $9 million in grants from the National Cancer Institute.

Clinical Centers of Excellence - Prostate Cancer: Johns Hopkins University by the numbers

Clinical Centers of Excellence – Prostate Cancer: Cleveland Clinic – Selection criteria

Clinical Centers of Excellence – Prostate Cancer: Cleveland Clinic by the numbers

The National Association For Continence (NAFC) announced Roger Dmochowski, MD, as the latest recipient of its Rodney Appell Continence Care Champion award.

UCLA has launched a patient-centered institute dedicated to developing therapies for the treatment of kidney, bladder, testicular, and prostate cancers.

Novasys Medical, Inc. (Newark, CA) recently announced that Noridian Administrative Services, LLC, a regional Medicare carrier, is now covering the non-surgical Renessa treatment for women with stress urinary incontinence.

New data analyses from a phase III clinical trial suggest favorable results using an investigational form of immunotherapy in men with prostate cancer.

Researchers have reported positive preliminary results from a phase II study of AT-101 in combination with docetaxel (Taxotere) and prednisone in men with docetaxel-refractory, castrate-resistant prostate cancer.

The discontinuation of routine PSA screening in certain elderly men may not increase the rates of undetected lethal disease and could avoid potentially unnecessary treatments and reduce diagnostic costs, according to a new study.

360 Network

This article provides an overview of the 2007 EAU-AUA Nephrolithiasis Guidelines.

This revised surgical approach uses a single suturing process that improves outcomes.

The nation is in the midst of a recession, and confidence in the economy continues to deteriorate. Many experts consider the health care industry to be more resilient than most, but how well a practice does depends on the decisions you make.

Today, targeted therapy is the first choice for most patients with metastatic renal cell carcinoma, but some patients can still be reasonably treated with immunotherapy, according to study results presented at the European Society for Medical Oncology 33rd Congress.

In patients with metastatic renal cell carcinoma treated with the novel compound pazopanib, tumor response could be correlated with several prognostic factors, investigators reported at the European Society for Medical Oncology 33rd Congress here.

Recent reports have suggested that single-incision laparoscopic surgery (SILS) is technically feasible.

First-line treatment with a novel agent known as sagopilone yields a high response rate and substantial decline in PSA in men with androgen-independent prostate cancer, according to findings presented at the European Society for Medical Oncology 33rd Congress.